Page last updated: 2024-09-04

pixantrone and Diffuse Mixed Small and Large Cell Lymphoma

pixantrone has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 33 studies

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (21.21)29.6817
2010's22 (66.67)24.3611
2020's4 (12.12)2.80

Authors

AuthorsStudies
Glavey, S; Morris, J; Murphy, P; O'Reilly, M; Quinn, J; Sargent, J1
Cencini, E; Fabbri, A1
Bocchia, M; Cencini, E; Consoli, C; Cuccaro, A; De Marco, F; Fabbri, A; Ghio, F; Rocco, M; Simonetti, F1
Bregni, M; de Barrenetxea Lekue, C; de Oteyza, JP; Grasso Cicala, S; Mombiedro, C; Navarro, B; Sancho, JM; Soler Campos, JA; Soler, B; Spione, M; Zinzani, PL1
Menna, P; Minotti, G; Salvatorelli, E1
Abastado, JP; Novack, SA; Perron, B; Therasse, P1
Coiffier, B; Egorov, A; Pettengell, R; Singer, J; Sivcheva, L1
Hübel, K1
Długosz-Danecka, M; Jurczak, W; Rivas Navarro, F1
Blajer-Olszewska, B; Chojnacki, T; Drozd-Sokołowska, J; Długosz-Danecka, M; Hus, I; Jurczak, W; Jurczyszyn, A; Puła, B; Raźny, M; Romejko-Jarosińska, J; Taszner, M1
Dunder, K; Flores, B; Gisselbrecht, C; Hudson, I; Laane, E; Péan, E; Pignatti, F; Salmonson, T; Sjöberg, J1
Hay, N; Landells, LJ; Prescott, C; Stevens, A; Sutcliffe, F1
Boyle, EM; Morschhauser, F1
Abastado, JP; Therasse, P1
Hatswell, AJ; Kadambi, A; Lanitis, T; Muszbek, N; Patel, D; Pettengell, R; Singer, JW; Wang, L1
Andorsky, D; Beck, JT; Belada, D; Dakhil, S; Daly, R; Dean, JP; Failloux, N; Georgiev, P; Hübel, K; Inhorn, LF; Pavlyuk, M; Pettengell, R; Quick, D1
Barosi, G; Corradini, P; Martelli, M; Minotti, G; Oliva, S; Spina, M; Tura, S; Zinzani, PL1
Keating, GM1
El-Helw, LM; Hancock, BW2
Mukherji, D; Pettengell, R2
Friedrich, MJ1
Borchmann, P; Cernohous, P; Engert, A; Herbrecht, R; Hess, G; Morschhauser, F; Singer, JW; Veals, SA; Wilhelm, M1
Cohen, GI; Fayad, LE; Kuepfer, C; Liebmann, JE; Modiano, MR; Pro, B; Romaguera, JE; Singer, JW; Srokowski, TP1
Jamal-Hanjani, M; Pettengell, R1
Boland, G; Cernohous, P; Coiffier, B; de Mendoza, FH; Digumarti, R; Gomez, H; Gorbatchevsky, I; Kuepfer, C; Narayanan, G; Pettengell, R; Rizzieri, D; Schiller, G; Singer, JW; Wang, L; Zinzani, PL1
Cabanillas, F1
Papadatos-Pastos, D; Pettengell, R1
Borchmann, P; Camboni, G; Engert, A; Gisselbrecht, C; Günther, H; Harousseau, JL; Morschhauser, F; Parry, A; Pfreundschuh, DM; Rudolph, C; Schnell, R; Wilhelm, M1
Borchmann, P; Schnell, R1
Engert, A; Gorbatchevsky, I; Herbrecht, R; Santoro, A; Zinzani, PL1
Bernareggi, A; Borchmann, P; Camboni, GM; Diehl, V; Engert, A; Hübel, K; Knippertz, R; Schnell, R; Schulz, A; Staak, JO; Staib, P1

Reviews

10 review(s) available for pixantrone and Diffuse Mixed Small and Large Cell Lymphoma

ArticleYear
An evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
    Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:16

    Topics: Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Prognosis; Topoisomerase II Inhibitors

2018
The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions.
    Future oncology (London, England), 2019, Volume: 15, Issue:3

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunotherapy, Adoptive; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Stem Cell Transplantation

2019
Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.
    Drugs, 2016, Volume: 76, Issue:16

    Topics: Adult; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Isoquinolines; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Rituximab

2016
Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas.
    Future oncology (London, England), 2009, Volume: 5, Issue:4

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Isoquinolines; Lymphoma, Non-Hodgkin

2009
Pixantrone maleate for non-Hodgkin's lymphoma.
    Drugs of today (Barcelona, Spain : 1998), 2009, Volume: 45, Issue:11

    Topics: Adult; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Topoisomerase II Inhibitors

2009
Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:11

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Isoquinolines; Lymphoma, Non-Hodgkin

2010
Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
    Expert opinion on drug metabolism & toxicology, 2011, Volume: 7, Issue:11

    Topics: Anthracyclines; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Drug Evaluation; Humans; Isoquinolines; Lymphoma, Non-Hodgkin

2011
Pixantrone: merging safety with efficacy.
    Expert review of hematology, 2013, Volume: 6, Issue:1

    Topics: Clinical Trials, Phase II as Topic; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Topoisomerase II Inhibitors

2013
The role of pixantrone in the treatment of non-Hodgkin's lymphoma.
    Expert opinion on investigational drugs, 2005, Volume: 14, Issue:8

    Topics: Animals; Antineoplastic Agents; DNA Topoisomerases, Type II; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Topoisomerase II Inhibitors

2005
Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.
    Expert opinion on investigational drugs, 2007, Volume: 16, Issue:10

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Neutropenia; Thrombocytopenia; Topoisomerase II Inhibitors

2007

Trials

9 trial(s) available for pixantrone and Diffuse Mixed Small and Large Cell Lymphoma

ArticleYear
Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.
    Clinical drug investigation, 2018, Volume: 38, Issue:6

    Topics: Adult; Aged; Europe; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Treatment Outcome

2018
The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma.
    Clinical therapeutics, 2016, Volume: 38, Issue:3

    Topics: Antineoplastic Agents; Cost-Benefit Analysis; Disease-Free Survival; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Quality-Adjusted Life Years; Recurrence; Retreatment; Secondary Prevention; Survival Rate; United Kingdom

2016
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
    Future oncology (London, England), 2016, Volume: 12, Issue:15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Research Design; Rituximab

2016
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Recurrence; Survival Analysis; Treatment Outcome; Vincristine

2011
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
    Cancer, 2011, Nov-15, Volume: 117, Issue:22

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Vidarabine

2011
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Salvage Therapy; Ventricular Function, Left

2012
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
    Haematologica, 2003, Volume: 88, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Recurrence; Thrombocytopenia; Topoisomerase II Inhibitors; Treatment Outcome

2003
EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma.
    Clinical lymphoma & myeloma, 2006, Volume: 7, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Relapsing Fever

2006
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Treatment Outcome

2001

Other Studies

14 other study(ies) available for pixantrone and Diffuse Mixed Small and Large Cell Lymphoma

ArticleYear
Pixantrone as a bridge to CAR-T treatment in high-grade transformation of follicular lymphoma.
    European journal of haematology, 2022, Volume: 109, Issue:5

    Topics: Humans; Isoquinolines; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen

2022
Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional TUSCAN Lymphoma Network)-Authors' reply to Morris and colleagues.
    European journal of haematology, 2022, Volume: 109, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Retrospective Studies; Rituximab

2022
Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone.
    European journal of haematology, 2023, Volume: 111, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Retrospective Studies

2023
Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
    European journal of haematology, 2020, Volume: 104, Issue:5

    Topics: Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Retreatment; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome

2020
Do You Know Pixantrone?
    Chemotherapy, 2017, Volume: 62, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Prednisone; Stem Cell Transplantation; Vincristine

2017
The Servier oncology pipeline in 2017.
    Future oncology (London, England), 2017, Volume: 13, Issue:17

    Topics: Apoptosis; Drug Discovery; Drug Industry; France; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Medical Oncology; Protein Kinase Inhibitors; Trifluridine

2017
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Pharmacological reports : PR, 2019, Volume: 71, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Transplantation, Autologous

2019
The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human u
    The oncologist, 2013, Volume: 18, Issue:5

    Topics: Adult; Anthracyclines; Drug Approval; European Union; Female; Humans; Isoquinolines; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Meta-Analysis as Topic; Recurrence; Risk Assessment; Treatment Outcome

2013
NICE guidance on pixantrone monotherapy for multiply relapsed or refractory aggressive non-Hodgkin lymphoma.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Cost-Benefit Analysis; Drug Approval; Drug Costs; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Practice Guidelines as Topic; Recurrence; Topoisomerase II Inhibitors; Treatment Outcome

2014
Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.
    Expert opinion on drug safety, 2015, Volume: 14, Issue:4

    Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Time Factors; Treatment Outcome

2015
Servier's pipeline in oncology: moving from research to patients.
    Future oncology (London, England), 2016, Volume: 12, Issue:5

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell- and Tissue-Based Therapy; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Drug Discovery; Drug Industry; Humans; Immunotherapy; Isoquinolines; Lymphoma, Non-Hodgkin; Medical Oncology; Neoplasms; Precision Medicine; Protein Engineering; Protein Kinase Inhibitors; Public-Private Sector Partnerships; Topoisomerase II Inhibitors; Translational Research, Biomedical

2016
Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.
    European journal of haematology, 2016, Volume: 97, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Management; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Practice Guidelines as Topic; Recurrence; Topoisomerase II Inhibitors

2016
Lymphoma researchers in search of molecular targets.
    Journal of the National Cancer Institute, 2010, Jul-21, Volume: 102, Issue:14

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials as Topic; Drug Approval; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Signal Transduction; United States; United States Food and Drug Administration

2010
Pixantrone: a new agent for relapsed aggressive lymphomas.
    The Lancet. Oncology, 2012, Volume: 13, Issue:7

    Topics: Antineoplastic Agents; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Salvage Therapy

2012